Telix Pharmaceuticals (ASX: TLX) Share Price

$13.59

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical company dedicated to pioneering molecularly targeted radiation (MTR) products. These innovations are developed for the diagnosis and treatment of various cancers and rare conditions, with its global presence encompassing Australia, Belgium, Japan, Switzerland, and the United States. The company's robust pipeline includes several leading candidates. TLX591-CDx is engineered for the diagnosis and treatment of metastatic castrate-resistant prostate cancer, while TLX66-CDx is designed for bone marrow conditioning and rare diseases. In advanced clinical development, TLX250-CDx is in Phase III trials for renal (kidney) cancer diagnosis and treatment, alongside TLX250 in Phase II for the same indication. TLX591 is also undergoing Phase III trials for metastatic castrate-resistant prostate cancer. For glioblastoma (brain cancer), TLX101 and TLX101-CDx are currently in Phase I/II studies, and TLX66 is in Phase I/IIa trials for bone marrow conditioning and rare diseases. Beyond these flagship programs, Telix is actively developing TLX592, a targeted alpha therapy candidate for prostate cancer. Its portfolio also features TLX591-Sx, a versatile PET tracer capable of both PET and fluorescent (optical) imaging, and TLX599-CDx, an investigational prostate cancer imaging agent utilizing single-photon emission computed tomography (SPECT). Strategic collaborations are integral to Telix's operations. This includes a significant license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for MTR product development, a scientific and clinical research alliance with Mauna Kea Technologies, and a strategic collaboration agreement with Lightpoint Medical, Ltd. Founded in 2015, the company's headquarters are located in North Melbourne, Australia.

Key Financial Data

TLX Frequently Asked Questions

Latest News

Similar Companies

Company	Market Cap	Price	P/E	Div Yield	1D Change
RHCRamsay Health Care Limited	$8.93B	$38.82	12.30	1.27%	▲+1.84%
ANNAnsell Limited	$4.13B	$29.27	9.32	1.24%	▲+0.97%
EBOEBOS Group Limited	$3.61B	$17.59	10.06	1.30%	▲+2.27%
MSBMesoblast Limited	$2.52B	$1.95	0.00	0.00%	▼-1.02%
NEUNeuren Pharmaceuticals Limited	$1.69B	$13.39	38.25	0.00%	▲+0.60%
CU6Clarity Pharmaceuticals Ltd	$801.9M	$2.15	-5.54	0.00%	▲+4.37%
CUVClinuvel Pharmaceuticals Limited	$451.7M	$8.96	14.96	0.40%	▲+1.24%
IMMImmutep Limited	$69.3M	$0.047	-3.40	0.00%	–+0.00%

ETFs That Hold TLX

TLX is held by 10 ASX-listed funds tracked on this site. The largest allocation is in VanEck - Australian Equal Weight ETF (ASX: MVW) at 0.85% of its portfolio.

Largest Healthcare Stocks on the ASX

Company	Market Cap	Price	1Y Change
CSLCSL Limited	$51.49B	$107.51	▼-55.35%
RMDResMed Inc.	$40.21B	$27.72	▼-28.70%
SIGSigma Healthcare Limited	$30.48B	$2.64	▼-18.01%
FPHFisher & Paykel Healthcare Corporation Limited	$18.93B	$32.23	▼-5.74%
PMEPro Medicus Limited	$17.13B	$164.00	▼-41.41%
MPLMedibank Private Limited	$13.69B	$4.97	▲+1.22%
SHLSonic Healthcare Limited	$9.98B	$20.20	▼-24.66%
RHCRamsay Health Care Limited	$8.93B	$38.82	▲+5.16%
COHCochlear Limited	$6.79B	$103.75	▼-62.07%
ANNAnsell Limited	$4.13B	$29.27	▼-5.54%

Browse all ASX sectors

Historical Prices